全反式维甲酸联合小剂量利妥昔单抗治疗激素抵抗或复发ITP的随机对照研究
本研究比较全反式维甲酸(ATRA)联合小剂量利妥昔单抗(LD-RTX)与单用LD-RTX在糖皮质激素抵抗或复发免疫性血小板减少症(ITP)患者中的疗效与安全性。按2:1随机分组,联合组112例、单药组56例。联合组总体反应率80% vs 单药组59%,持续反应率61% vs 41%,差异均显著。联合组最常见不良事件为皮肤干燥和头痛或头晕。
要点
- ATRA联合LD-RTX较单用LD-RTX显著提高激素抵抗或复发ITP的总体反应率(80% vs 59%)。
- 联合组持续反应率亦显著高于单药组(61% vs 41%),差异有统计学意义。
- 联合治疗安全性可控,常见不良事件为皮肤干燥和头痛或头晕。
核心结论
- ATRA联合LD-RTX可显著提高糖皮质激素抵抗或复发成人ITP患者的总体反应率和持续反应率,是有前景的治疗选择。
研究设计与样本
- 随机对照试验,按2:1随机分为ATRA联合LD-RTX组112例和LD-RTX单药组56例。
- 研究对象为糖皮质激素抵抗或复发的ITP患者。
- 研究注册号NCT03304288。
主要发现
- 1年内总体反应率联合组80% vs 单药组59%,组间差异0.22(95%CI 0.07-0.36)。
- 持续反应率联合组61%(68例)vs 单药组41%(23例),组间差异0.20(95%CI 0.04-0.35)。
- 联合组最常见不良事件为皮肤干燥和头痛或头晕。
关键数值与推荐
- 总体反应定义:入组后1年内血小板计数≥30×10^9/L且至少2次独立确认(间隔≥7天),基线血小板计数至少翻倍,未接受其他ITP特异性治疗,且无出血。
- 持续反应定义:入组后1年内达到总体反应后连续6个月维持血小板计数>30×10^9/L、无出血且无需其他ITP特异性治疗。
临床怎么用
- 对于糖皮质激素抵抗或复发的成人ITP,可考虑ATRA联合LD-RTX方案以提高总体和持续反应率。
- 治疗期间需关注皮肤干燥及头痛或头晕等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The study aimed to compare the efficacy and safety of all-trans retinoic acid (ATRA) plus low-dose rituximab (LD-RTX) with LD-RTX monotherapy in corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients. Recruited patients were randomized at a ratio of 2:1 into 2 groups: 112 patients received LD-RTX plus ATRA, and 56 patients received LD-RTX monotherapy. Overall response (OR), defined as achieving a platelet count of ≥30 × 109/L confirmed on ≥2 separate occasions (≥7 days apart), at least a doubling of the baseline platelet count without any other ITP-specific treatment, and the absence of bleeding within 1 year after enrollment, was observed in more patients in the LD-RTX plus ATRA group (80%) than in the LD-RTX monotherapy group (59%) (between-group difference, 0.22; 95% CI, 0.07-0.36). Sustained response (SR), defined as maintenance of a platelet count >30 × 109/L, an absence of bleeding, and no requirement for any other ITP-specific treatment for 6 consecutive months after achievement of OR during 1 year following enrollment, was achieved by 68 (61%) patients in the combination group and 23 (41%) patients in the monotherapy group (between-group difference, 0.20; 95% CI, 0.04-0.35). The 2 most common adverse events (AEs) for the combination group were dry skin and headache or dizziness. Our findings demonstrated that ATRA plus LD-RTX significantly increased the overall and sustained response, indicating a promising treatment option for corticosteroid-resistant or relapsed adult ITP. This study is registered at www.clinicaltrials.gov as #NCT03304288.
引用
- Wu YJ, Liu H, Zeng QZ, et al. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2022. PMID: 34665865. doi:10.1182/blood.2021013393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。